Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 11/20 | 0.75 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.75 |
| ▸ | BUB1 | O43683 | 1/20 | 0.75 |
| ▸ | PRKACG | P22612 | 1/20 | 0.75 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.75 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.75 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.75 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686938 | 0.91 | MAPK14 (0.75) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL4680637 | 0.89 | MAPK14 (0.72) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448612 | 0.89 | MAPK14 (0.77) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448733 | 0.87 | MAPK14 (0.72) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| Losmapimod SCHEMBL29888732 | 0.86 | MAPK14 (1.00) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| Losmapimod SCHEMBL1070401 | 0.86 | MAPK14 (1.00) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| Losmapimod SCHEMBL29367949 | 0.86 | MAPK14 (1.00) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20460604 | 0.85 | MAPK14 (0.67) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL4681674 | 0.85 | MAPK14 (0.66) | MAPK14CYP2C9MAPK11BUB1PRKACG | |
| SCHEMBL20448678 | 0.84 | MAPK14 (0.86) | MAPK14CYP2C9MAPK11BUB1PRKACG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214623-A1 | N-(2,2-Dimethylpropyl)-6- -3-Pyridinecarboxamide | CHANDI AMRIK | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214623-A1 | N-(2,2-Dimethylpropyl)-6- -3-Pyridinecarboxamide | MAPKAPK2, MAP3K2, MAP4K2 | MAPK14 33/4885CYP2C9 4135/4885MAPK11 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.